RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum
tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients
with advanced solid tumors that are refractory after standard of care therapy for the
disease. The results of this study will help provide clinical information for the design and
conduct of further clinical studies with RTA 408 in cancer patients.